C3-targeted therapy in periodontal disease: moving closer to the clinic

Contributing authors

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Complement plays a key role in immunosurveillance and homeostasis. When dysregulated or overactivated, complement can become a pathological effector, as seen in several inflammatory disorders, including periodontal disease. Recently, clinical correlative studies and preclinical mechanistic investigations have collectively demonstrated that complement is hyperactivated during periodontitis and that targeting its central component (C3) provides therapeutic benefit in nonhuman primates (NHPs). The preclinical efficacy of a C3-targeted drug candidate combined with excellent safety and pharmacokinetic profiles supported its use in a recent Phase IIa clinical study in which C3 inhibition resolved gingival inflammation in patients with periodontal disease. We posit that C3-targeted intervention might represent a novel and transformative host-modulation therapy meriting further investigation in Phase III clinical trials for the treatment of periodontitis.

Original languageEnglish (US)
Pages (from-to)856-864
Number of pages9
JournalTrends in Immunology
Issue number10
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'C3-targeted therapy in periodontal disease: moving closer to the clinic'. Together they form a unique fingerprint.

Cite this